exenatide
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetes Complications
Conditions
Diabetes Complications, Fatty Liver
Trial Timeline
Oct 1, 2007 → Feb 1, 2010
NCT ID
NCT00529204About exenatide
exenatide is a phase 2 stage product being developed by Eli Lilly for Diabetes Complications. The current trial status is terminated. This product is registered under clinical trial identifier NCT00529204. Target conditions include Diabetes Complications, Fatty Liver.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01373216 | Phase 3 | Completed |
| NCT01056549 | Pre-clinical | Completed |
| NCT00753896 | Phase 3 | Completed |
| NCT00529204 | Phase 2 | Terminated |
| NCT00516048 | Phase 3 | Completed |
| NCT01876849 | Phase 3 | Completed |
Competing Products
20 competing products in Diabetes Complications